RxDoctor Payments Data

Dean Floyd, MD

Family Medicine · West Columbia, SCNPI 1386605285

Payments from drug & device makers

$2,398in general payments, 2019–2025

Across 130 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$534
  • Abbott$467
  • Lilly USA, LLC$331
  • Sanofi-aventis U.S. LLC$243
  • AbbVie$240
  • AstraZeneca$163
  • plus $420 from 10 others

What the payments were for

  • Food & beverage$2,38499%
  • Entertainment$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,398 in reported general payments places this provider in the 75th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$4,786
Medicare patients
121
Services billed
301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide138$159,306
OzempicSemaglutide84$117,246
Humira(Cf) PenAdalimumab13$90,617
EliquisApixaban44$56,776
FarxigaDapagliflozin Propanediol43$37,046
JardianceEmpagliflozin34$31,522
TrulicityDulaglutide22$29,148
RybelsusSemaglutide20$23,508
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$16,945
JanuviaSitagliptin Phosphate15$15,011
LinzessLinaclotide12$12,627
Lantus SolostarInsulin Glargine,hum.Rec.Anlog88$10,276
Novolog FlexpenInsulin Aspart30$7,477
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro27$5,441
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp16$4,115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$331$188,453160 claims
Novo NordiskOzempic, Rybelsus$534$140,754104 claims
PfizerEliquis$77$56,77644 claims
AstraZenecaFarxiga$163$37,04643 claims
GSKTrelegy Ellipta, Arnuity Ellipta$26$19,35323 claims
MerckJanuvia$28$15,01115 claims
AbbVieLinzess$240$12,62712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in West Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →